PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNitrofurantoin
Nitrofurantoin
Furadantin, Ivadantin, Macrobid, Macrocrystalline, Macrodantin, Nitrofurantoin, Nitrofurantoin Nitrofurantoin (nitrofurantoin) is a small molecule pharmaceutical. Nitrofurantoin was first approved as Furadantin on 1982-01-01. It is used to treat bacterial infections, escherichia coli infections, klebsiella infections, staphylococcal infections, and urinary tract infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
Trade Name
FDA
EMA
Furadantin, Macrodantin, Nitrofurantoin (discontinued: Furadantin, Furalan, Ivadantin, Nitrofurantoin, Nitrofurantoin macrocrystalline)
Combinations
Macrobid, Nitrofurantoin (monohydrate/macrocrystals) (discontinued: Nitrofurantoin (monohydrate/macrocrystals))
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nitrofurantoin
+
Nitrofurantoin
+
macrocrystalline
Tradename
Company
Number
Date
Products
MACROBIDAlmatica PharmaN-020064 RX1991-12-24
1 products, RLD, RS
Nitrofurantoin
Tradename
Company
Number
Date
Products
FURADANTINCasper PharmaN-009175 RX1982-01-01
2 products, RLD
Show 1 discontinued
Nitrofurantoin sodium
Tradename
Company
Number
Date
Products
IVADANTINProcter And GambleN-012402 DISCN1982-01-01
1 products
Hide discontinued
Nitrofurantoin
+
macrocrystalline
Tradename
Company
Number
Date
Products
MACRODANTINAlmatica PharmaN-016620 RX1982-01-01
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
furadantinNew Drug Application2024-03-28
macrobidNew Drug Application2025-03-17
macrodantinNew Drug Application2023-06-01
nitrofurantion macrocrystalsNew Drug Application2018-06-05
nitrofurantoinANDA2025-03-26
nitrofurantoin (macrocrystals)ANDA2024-10-15
nitrofurantoin (monohydrate/macrocrystals)ANDA2025-03-26
nitrofurantoin macrocrystalsANDA2025-04-09
nitrofurantoin monoNew Drug Application2022-10-09
nitrofurantoin monohydrate macrocrystallineNew Drug Application2020-12-14
Show 4 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
urinary tract infectionsEFO_0003103D014552N39.0
bacterial infections—D001424A49
escherichia coli infectionsEFO_1001318D004927B96.20
staphylococcal infections—D013203A49.01
klebsiella infectionsEFO_1001353D007710—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XE: Nitrofuran derivatives, antibacterials for systemic use
— J01XE01: Nitrofurantoin
— J01XE51: Nitrofurantoin, combinations
HCPCS
No data
Clinical
Clinical Trials
76 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary tract infectionsD014552EFO_0003103N39.0—1———1
CystitisD003556EFO_1000025N30—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNitrofurantoin
INNnitrofurantoin
Description
Nitrofurantoin is an imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA. It has a role as a hepatotoxic agent, an antiinfective agent and an antibacterial drug. It is an organonitrogen heterocyclic antibiotic, an organooxygen heterocyclic antibiotic, a nitrofuran antibiotic and an imidazolidine-2,4-dione. It is functionally related to a semicarbazide.
Classification
Small molecule
Drug classantiepileptics (hydantoin derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
Identifiers
PDB—
CAS-ID67-20-9
RxCUI—
ChEMBL IDCHEMBL572
ChEBI ID71415
PubChem CID6604200
DrugBankDB00698
UNII ID927AH8112L (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Nitrofurantoin – RVL Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Nitrofurantoin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 13,848 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
8,511 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use